High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.896
+46.88%
--
--
-0.880
+31.34%
--
--
-0.876
-10.59%
Estimates Revision
The market is revising Downward the revenue expectations for Scholar Rock Holding Corporation (SRRK) for FY2025, with the revenue forecasts being adjusted by -96.87% over the past three months. During the same period, the stock price has changed by 43.90%.
Revenue Estimates for FY2025
Revise Downward
-96.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.48%
In Past 3 Month
Stock Price
Go Up
+43.90%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 46.82 USD with a low forecast of 42.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 45.200
Low
42.00
Averages
46.82
High
51.00
Current: 45.200
Low
42.00
Averages
46.82
High
51.00
JPMorgan
NULL -> Overweight
maintain
$46 -> $47
2025-11-18
Reason
JPMorgan
Price Target
$46 -> $47
2025-11-18
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Scholar Rock to $47 from $46 and keeps an Overweight rating on the shares. The firm updated the company's model.
Wolfe Research
Outperform
initiated
$42
2025-11-17
Reason
Wolfe Research
Price Target
$42
2025-11-17
initiated
Outperform
Reason
Wolfe Research initiated coverage of Scholar Rock with an Outperform rating and $42 price target. Scholar Rock's manufacturing "hiccup is just a detour, not a derailment," argues the analyst, who forecasts apitegromab to achieve blockbuster sales given its non-overlapping mechanism.
Barclays
NULL -> Overweight
maintain
$44 -> $45
2025-11-17
Reason
Barclays
Price Target
$44 -> $45
2025-11-17
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Scholar Rock to $45 from $44 and keeps an Overweight rating on the shares following the Q3 report.
BMO Capital
BMO Capital
Outperform
maintain
$45 -> $50
2025-11-14
Reason
BMO Capital
BMO Capital
Price Target
$45 -> $50
2025-11-14
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Scholar Rock to $50 from $45 and keeps an Outperform rating on the shares. With Novo's Catalent site still requiring a reinspection before apitegromab can be approved, management has moved to accelerate tech transfer of commercial capacity for a second fill finish facility, the firm notes. Novo continues to project confidence in a successful year-end reinspection, but BMO believes Scholar Rock's prudent second facility preparations are likely to improve confidence in a 2026 approval of apitegromab. Non-dilutive financing also provides more stability for Scholar Rock as they continue to wait for their first commercial approval, the firm adds.
BofA
Tazeen Ahmad
Buy
downgrade
$53 -> $49
2025-10-28
Reason
BofA
Tazeen Ahmad
Price Target
$53 -> $49
2025-10-28
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Scholar Rock to $49 from $53 and keeps a Buy rating on the shares. After speaking with a former director at FDA's Office of Inspections and Investigations and with a former site inspector who previously inspected Catalent Indiana to better understand timelines and next steps for Scholar Rock following CI's OAI classification, the firm now assumes "a bit more conservative" mid-2027 apitegromab launch timeline, the analyst tells investors.
Barclays
Etzer Darout
Overweight
maintain
$45 -> $44
2025-09-24
Reason
Barclays
Etzer Darout
Price Target
$45 -> $44
2025-09-24
maintain
Overweight
Reason
Barclays analyst Etzer Darout lowered the firm's price target on Scholar Rock to $44 from $45 and keeps an Overweight rating on the shares after the FDA issued a complete response letter for apitegromab in spinal muscular atrophy due to Catalent, Indiana, manufacturing plant issues. The firm says that while the letter is "not ideal," the impact to Scholar Rock should be "muted."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Scholar Rock Holding Corp (SRRK.O) is -12.41, compared to its 5-year average forward P/E of -7.80. For a more detailed relative valuation and DCF analysis to assess Scholar Rock Holding Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.80
Current PE
-12.41
Overvalued PE
-3.27
Undervalued PE
-12.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.42
Undervalued EV/EBITDA
-7.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
38.66
Current PS
0.00
Overvalued PS
104.19
Undervalued PS
-26.87
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SRRK News & Events
Events Timeline
(ET)
2025-11-14
12:00:37
Scholar Rock sees a 25.3% increase.
2025-11-14
10:00:36
Scholar Rock sees a 28.9% increase.
2025-11-14
08:46:33
Scholar Rock anticipates third-party facility will be prepared for reinspection by year-end.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
4.0
11-18BenzingaJP Morgan Keeps Overweight Rating on Scholar Rock Holding and Increases Price Target to $47
Preview
6.0
11-17BenzingaBarclays Keeps Overweight Rating on Scholar Rock Holding and Increases Price Target to $45
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/973367d13378aa4b25262e2ad02a56561641db7edaac023b8da9704cc5c3cd1c.jpeg)
Preview
4.5
11-16TipRanksFriday's Major Stock Market Highlights: Morning News Summary!
Sign Up For More News
People Also Watch
FAQ
What is Scholar Rock Holding Corp (SRRK) stock price today?
What is Scholar Rock Holding Corp (SRRK)'s business?
What is the price predicton of SRRK Stock?
What is Scholar Rock Holding Corp (SRRK)'s revenue for the last quarter?
What is Scholar Rock Holding Corp (SRRK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Scholar Rock Holding Corp (SRRK)'s fundamentals?
How many employees does Scholar Rock Holding Corp (SRRK). have?